{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:58:47Z","timestamp":1790132327649,"version":"4.0.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,8,21]],"date-time":"2011-08-21T00:00:00Z","timestamp":1313884800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1007\/s11102-011-0341-0","type":"journal-article","created":{"date-parts":[[2011,8,20]],"date-time":"2011-08-20T04:56:07Z","timestamp":1313816167000},"page":"37-43","source":"Crossref","is-referenced-by-count":85,"title":["New targeted therapies in pituitary carcinoma resistant to temozolomide"],"prefix":"10.1007","volume":"15","author":[{"given":"Emmanuel","family":"Jouanneau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Wierinckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Ducray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Favrel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Borson-Chazot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Honnorat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Trouillas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rald","family":"Raverot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,8,21]]},"reference":[{"key":"341_CR1","doi-asserted-by":"crossref","unstructured":"Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M, Grossman AB (2005) Diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab 90(5):3089\u20133099. doi: 10.1210\/jc.2004-2231","DOI":"10.1210\/jc.2004-2231"},{"issue":"12","key":"341_CR2","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1210\/jc.83.12.4233","volume":"83","author":"GA Kaltsas","year":"1998","unstructured":"Kaltsas GA, Mukherjee JJ, Plowman PN, Monson JP, Grossman AB, Besser GM (1998) The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors. J Clin Endocrinol Metab 83(12):4233\u20134238","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"341_CR3","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(06)70728-8","volume":"7","author":"S Lim","year":"2006","unstructured":"Lim S, Shahinian H, Maya MM, Yong W, Heaney AP (2006) Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol 7(6):518\u2013520","journal-title":"Lancet Oncol"},{"issue":"10","key":"341_CR4","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1210\/jc.2010-0644","volume":"95","author":"G Raverot","year":"2010","unstructured":"Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron P, Chabre O, Chanson P, Cortet-Rudelli C, Assaker R, Dufour H, Gaillard S, Francois P, Jouanneau E, Passagia J-G, Bernier M, Cornelius A, Figarella-Branger D, Trouillas J, Borson-Chazot F, Brue T (2010) Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab 95(10):4592\u20134599","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"341_CR5","doi-asserted-by":"crossref","first-page":"E280","DOI":"10.1210\/jc.2010-0441","volume":"95","author":"ZM Bush","year":"2010","unstructured":"Bush ZM, Longtine JA, Cunningham T, Schiff D, Jane JA, Vance ML, Thorner MO, Laws ER, Lopes MBS (2010) Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O6-methylguanine methyltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metab 95(11):E280\u2013E290. doi: 10.1210\/jc.2010-0441","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"341_CR6","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1530\/EJE-10-0629","volume":"163","author":"M Losa","year":"2010","unstructured":"Losa M, Mazza E, Terreni MR, McCormack A, Gill AJ, Motta M, Cangi MG, Talarico A, Mortini P, Reni M (2010) Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. Eur J Endocrinol 163(6):843\u2013851. doi: 10.1530\/eje-10-0629","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"341_CR7","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1677\/ERC-09-0101","volume":"16","author":"D Dworakowska","year":"2009","unstructured":"Dworakowska D, Wlodek E, Leontiou CA, Igreja S, Cakir M, Teng M, Prodromou N, Goth MI, Grozinsky-Glasberg S, Gueorguiev M, Kola B, Korbonits M, Grossman AB (2009) Activation of RAF\/MEK\/ERK and PI3K\/AKT\/mTOR pathways in pituitary adenomas and their effects on downstream effectors. Endocr Relat Cancer 16(4):1329\u20131338. doi: ERC-09-0101[pii]10.1677\/ERC-09-0101","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"341_CR8","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"JC Yao","year":"2011","unstructured":"Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Oberg K (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364(6):514\u2013523. doi: 10.1056\/NEJMoa1009290","journal-title":"N Engl J Med"},{"issue":"3","key":"341_CR9","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1677\/ERC-08-0269","volume":"16","author":"A Gorshtein","year":"2009","unstructured":"Gorshtein A, Rubinfeld H, Kendler E, Theodoropoulou M, Cerovac V, Stalla GK, Cohen ZR, Hadani M, Shimon I (2009) Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro. Endocr Relat Cancer 16(3):1017\u20131027. doi: ERC-08-0269[pii]10.1677\/ERC-08-0269","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"341_CR10","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1210\/jc.2009-1641","volume":"95","author":"MC Zatelli","year":"2010","unstructured":"Zatelli MC, Minoia M, Filieri C, Tagliati F, Buratto M, Ambrosio MR, Lapparelli M, Scanarini M, degli Uberti EC (2010) Effect of everolimus on cell viability in nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 95(2):968\u2013976. doi: 10.1210\/jc.2009-1641","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"341_CR11","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1158\/0008-5472.CAN-09-2951","volume":"70","author":"V Cerovac","year":"2010","unstructured":"Cerovac V, Monteserin-Garcia J, Rubinfeld H, Buchfelder M, Losa M, Florio T, Paez-Pereda M, Stalla GK, Theodoropoulou M (2010) The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells. Cancer Res 70(2):666\u2013674. doi: 0008-5472.CAN-09-2951[pii]10.1158\/0008-5472.CAN-09-2951","journal-title":"Cancer Res"},{"key":"341_CR12","unstructured":"Jouanneau E, Ducluzeau PH, Tilikete C, Borson-Chazot F, Trouillas J, Perrin G (2001) Should silent corticotroph-cell adenoma be classified as a non-functional pituitary adenoma? Neurochirurgie 47(2\u20133 Pt 1):128\u2013132"},{"key":"341_CR13","doi-asserted-by":"crossref","unstructured":"Raverot G, Wierinckx A, Jouanneau E, Auger C, Borson-Chazot F, Lachuer J, Pugeat M, Trouillas J (2010) Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and with Cushing\u2019s disease. Eur J Endocrinol doi: 10.1530\/EJE-10-0076","DOI":"10.1530\/EJE-10-0076"},{"issue":"9","key":"341_CR14","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1210\/jc.2002-020309","volume":"87","author":"CJ McCabe","year":"2002","unstructured":"McCabe CJ, Boelaert K, Tannahill LA, Heaney AP, Stratford AL, Khaira JS, Hussain S, Sheppard MC, Franklyn JA, Gittoes NJ (2002) Vascular endothelial growth factor, its receptor KDR\/Flk-1, and pituitary tumor transforming gene in pituitary tumors. J Clin Endocrinol Metab 87(9):4238\u20134244","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"341_CR15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1677\/ERC-06-0026","volume":"14","author":"MC Zatelli","year":"2007","unstructured":"Zatelli MC, Piccin D, Vignali C, Tagliati F, Ambrosio MR, Bondanelli M, Cimino V, Bianchi A, Schmid HA, Scanarini M, Pontecorvi A, De Marinis L, Maira G, degli Uberti EC (2007) Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Endocr Relat Cancer 14(1):91\u2013102. doi: 14\/1\/91[pii]10.1677\/ERC-06-0026","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"341_CR16","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1124\/jpet.110.177790","volume":"337","author":"GM Luque","year":"2011","unstructured":"Luque GM, Perez-Millan MI, Ornstein AM, Cristina C, Becu-Villalobos D (2011) Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas. J Pharmacol Exp Ther 337(3):766\u2013774. doi: 10.1124\/jpet.110.177790","journal-title":"J Pharmacol Exp Ther"},{"key":"341_CR17","doi-asserted-by":"crossref","unstructured":"Fukuoka H, Cooper O, Mizutani J, Tong Y, Ren SG, Bannykh S, Melmed S (2011) HER2\/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy. Mol Endocrinol doi:me.2010-0353 [pii] 10.1210\/me.2010-0353","DOI":"10.1210\/me.2010-0353"},{"issue":"20","key":"341_CR18","doi-asserted-by":"crossref","first-page":"8414","DOI":"10.1073\/pnas.1018091108","volume":"108","author":"NA Liu","year":"2011","unstructured":"Liu NA, Jiang H, Ben-Shlomo A, Wawrowsky K, Fan XM, Lin S, Melmed S (2011) Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor. Proc Natl Acad Sci USA 108(20):8414\u20138419. doi: 1018091108[pii]10.1073\/pnas.1018091108","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"341_CR19","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1210\/jc.2009-1191","volume":"95","author":"G Raverot","year":"2010","unstructured":"Raverot G, Wierinckx A, Dantony E, Auger C, Chapas G, Villeneuve L, Brue T, Figarella-Branger D, Roy P, Jouanneau E, Jan M, Lachuer J, Trouillas J (2010) Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up. J Clin Endocrinol Metab 95(4):1708\u20131716. doi: jc.2009-1191[pii]10.1210\/jc.2009-1191","journal-title":"J Clin Endocrinol Metab"},{"key":"341_CR20","doi-asserted-by":"crossref","unstructured":"Wierinckx A, Raverot G, Nazaret N, Jouanneau E, Auger C, Lachuer J, Trouillas J (2010) Proliferation markers of human pituitary tumors: contribution of a genome-wide transcriptome approach. Mol Cell Endocrinol doi: 10.1016\/j.mce.2010.02.043","DOI":"10.1016\/j.mce.2010.02.043"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-011-0341-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11102-011-0341-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-011-0341-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T05:58:18Z","timestamp":1560491898000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11102-011-0341-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,21]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["341"],"URL":"https:\/\/doi.org\/10.1007\/s11102-011-0341-0","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,21]]}}}